Michael Khan
Director Ejecutivo en Argonaute RNA Ltd. .
Perfil
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd.
He is also a member of Diabetes UK and HEART UK.
Previously, he was the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also worked as the Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Cargos activos de Michael Khan
| Empresas | Cargo | Inicio |
|---|---|---|
| HEART UK | Corporate Officer/Principal | - |
| Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
 Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Director Ejecutivo | 01/01/2021 |
Antiguos cargos conocidos de Michael Khan.
| Empresas | Cargo | Fin |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Director Técnico/Científico/I+D | 17/06/2016 |
| University of Warwick | Corporate Officer/Principal | - |
Formación de Michael Khan.
| University College London | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| SILENCE THERAPEUTICS PLC | Commercial Services |
| Empresas privadas | 3 |
|---|---|
| Diabetes UK | |
| HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Argonaute RNA Ltd. develops safe and reliable methods of temporarily silencing target genes in different tissue cells. The company is based in Bristol, UK. Michael Khan has been the CEO of the British company since 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Michael Khan